Refine by
Inflammatory Bowel Articles & Analysis: Older
58 news found
Dysbiosis of intestinal flora is closely associated with the development of many diseases, such as obesity, diabetes, non-alcoholic fatty liver, inflammatory bowel disease, and tumors. “We employ state-of-the-art analytical platforms for gut microbiota metabolomics studies, including GC-MS, LC-MS, and UPLC-MS. ...
Bioactive lipids are consistently involved in chronic inflammation for pathological characterization, such as cancer, diabetes, atherosclerosis, asthma, inflammatory bowel disease, as well as autoimmune and neurodegenerative disorders. ...
The implementation of AIR will aid in the recruitment of patients for clinical trials focused on inflammatory bowel disease (IBD). Both One GI® and Iterative Scopes are fast-growing innovators in the gastroenterology space. ...
About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. ...
This strategic partnership will lay the groundwork for future collaborations by using AIR to aid in the recruitment of patients for clinical trials in inflammatory bowel disease (IBD) and expanding Gastro Health’s clinical research capabilities. ...
About Iterative Health Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. ...
Lumen's clinical pipeline includes investigational biologic drugs for C. difficile infection, Covid-19, cardiometabolic disease, inflammatory bowel disease, norovirus, and traveler's diarrhea. ...
With targeted investments, we continue to make important progress in developing next-generation best-in-class candidates that reach optimal target coverage, teasing apart selectivity profiles that indicate the potential of SIK3i for rheumatological indications and SIK2/3i for inflammatory bowel disease. Our most advanced candidate, SIK3 inhibitor ‘4399, has ...
AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease (IBD) clinical trials. Recruiting qualified patients is one of the most significant and expensive challenges of clinical trials, but AI-R helps determine if patients are ...
About Iterative Scopes Iterative Scopes is a pioneer in the application of artificial intelligence-based precision medicine for gastroenterology with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). The technology is also designed to potentially enhance colorectal cancer screenings. ...
The Phase 1 studies of VE202 (a defined bacterial consortium candidate for inflammatory bowel disease) and VE818 (a defined bacterial consortium candidate for an undisclosed indication) were similarly designed double-blind, placebo-controlled studies in healthy adults, enrolling a total of 31 and 74 subjects, respectively. ...
” About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. ...
ByBiomX
” About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. ...
ByBiomX
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. ...
About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. ...
ByBiomX
Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc. ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). The project, to support the ongoing development of Microbiotica’s ...
“We believe that CAR-Tregs are the next frontier of cell therapy and represent a potentially transformational approach to solid organ transplantation as well as to many challenging autoimmune and inflammatory conditions. The STEADFAST Phase 1/2 study is an important milestone for genomic medicine that we anticipate will yield insights regarding CAR-Treg biology and could ...
” Beyond campylobacter, Lumen is currently applying the technology to a growing list of highly prevalent diseases, including the following publicly disclosed programs: LMN-201, a complex biologic cocktail for prevention of C. difficile infection (in collaboration with National Institute of Allergy and Infectious Diseases (NIAID) and Rockefeller University) LMN-301, an antibody cocktail ...
Therefore, the complex interaction mechanism between enteroviruses and other gut microbes and the host is considered to be an important factor affecting and intervening in various diseases such as intestinal infectious diseases, inflammatory bowel diseases and intestinal tumors,” said a senior scientist at Creative Proteomics. ...